ABX-002 IND Clearance: Optionality Without Evidence, Mechanism Without Disclosure

FDA Clears IND for Autobahn's ABX-002 in Bipolar Depression

Autobahn Therapeutics announced that the U.S. FDA has cleared its Investigational New Drug (IND) application for ABX-002, allowing the company to initiate a Phase 2 trial for ABX-002 as an adjunctive treatment for bipolar depression. The company plans to start this trial by the end of 2024. ABX-002 is also currently being evaluated in the AMPLIFY Phase 2 trial for major depressive disorder, with topline data expected in the second half of 2025. This clearance expands Autobahn's depression treatment program, addressing a significant unmet need in bipolar disorder.

• The FDA's IND clearance enables Autobahn Therapeutics to proceed with a Phase 2 trial for ABX-002 in adult patients with depressive episodes associated with bipolar I or bipolar II disorder. This trial, expected to begin by yearend 2024, aims to establish biological and clinical proof-of-concept, evaluating endpoints such as changes in brain energy metabolism via phosphorus magnetic resonance spectroscopy (31P-MRS) and depressive symptoms using the Hamilton Depression Rating Scale (HAMD).
• ABX-002 is an oral, highly potent, and selective thyroid hormone beta receptor (TRβ) agonist. It is designed to enhance the central nervous system (CNS) benefits of thyroid hormone biology while minimizing peripheral side effects. This mechanism targets cellular energy metabolism pathways, which are crucial for brain bioenergetics and may be particularly effective for atypical depression symptoms, a prevalent and underserved sub-population.
• The IND clearance for bipolar depression expands Autobahn's clinical development for ABX-002, which is already in an ongoing AMPLIFY Phase 2 trial for major depressive disorder (MDD), with topline data anticipated in the second half of 2025. This dual focus underscores the company's commitment to addressing the significant unmet need for safe and effective therapies specifically targeting depressive symptoms in both bipolar disorder and MDD.

Addressing the Unmet Needs in Bipolar Depression Treatment

Bipolar depression remains one of the most difficult-to-treat psychiatric conditions, with current pharmacological options offering limited efficacy, significant tolerability concerns, and meaningful risks of mood destabilization. The heterogeneity of the disorder — compounded by frequent psychiatric and medical comorbidities — further complicates both diagnosis and treatment selection.

• Limited approved therapies and guideline options. Current guidelines provide few approved treatment options for bipolar depression. Among atypical antipsychotics, olanzapine-fluoxetine combination (OFC) and quetiapine (IR and XR formulations) are FDA-approved, with lurasidone also demonstrating superiority over placebo; however, aripiprazole and ziprasidone showed no significant difference from placebo in response or remission. Direct comparative trials between the only two approved products — OFC and quetiapine — are not available, limiting head-to-head guidance for clinical decision-making.

• Antidepressant use remains controversial due to switch risk and uncertain efficacy. Despite approximately 50–60% of individuals with bipolar disorder being prescribed antidepressants, their benefit is not established. In a double-blind, placebo-controlled study, 23.5% of subjects receiving a mood stabilizer plus adjunctive antidepressant achieved durable recovery (8 consecutive weeks of euthymia), compared with 27.3% receiving mood stabilizer plus placebo (P=0.40), with modest nonsignificant trends favoring the placebo group across secondary outcomes. Among patients with prior antidepressant exposure in the STEP-BD program, 44% reported at least one treatment-emergent switch to mania or hypomania. Switch risk was significantly elevated with tricyclic antidepressants (OR=7.80, 95% CI=1.56–28.9), serotonin reuptake inhibitors (OR=3.73, 95% CI=1.98–7.05), and bupropion (OR=4.28, 95% CI=1.72–10.6).

• Tolerability burdens limit long-term use of approved agents. Among FDA-approved atypical antipsychotics, the differences in NNTs for response and remission are small, but differences in NNHs for discontinuation due to adverse events and common side effects are large. Olanzapine monotherapy and OFC carry the smallest NNHs for ≥7% weight gain (both NNH=5); quetiapine-XR has an NNH of 4 for somnolence; and aripiprazole has an NNH of 5 for akathisia — underscoring that agent selection should be driven primarily by safety and tolerability profiles.

• Medication nonadherence is prevalent and linked to executive dysfunction. In a study of 200 euthymic bipolar I disorder patients, 54.5% had low medication adherence. Low-adherent patients demonstrated significantly poorer performance on response inhibition (higher commission errors on Go/No-Go; F[1]=7.63, p=0.006) and cognitive flexibility (higher perseveration errors on the Wisconsin Card Sorting Test; F[1]=8.61, p=0.004), suggesting that neurocognitive deficits intrinsic to the disorder itself undermine the consistent medication use required for effective management.

• Substantial economic burden driven by suboptimal clinical management. The total annual national economic burden of bipolar disorder and bipolar I disorder in the United States exceeds $195 billion, with approximately 25% attributed to direct medical costs. Indirect costs — including unemployment and lost work productivity for patients and caregivers — account for 72–80% of this burden. Key drivers of higher direct costs include frequent psychiatric interventions, comorbid conditions, and both suboptimal medication adherence and clinical management, highlighting the systemic consequences of current treatment gaps.

• Real-world complexity is inadequately captured in clinical trials. Strict inclusion criteria in randomized controlled trials frequently fail to account for the intricacies of real-world practice, including the natural mood fluctuations of bipolar disorder and the high prevalence of comorbid conditions such as anxiety. The identification of individualized predictors of antidepressant response — such as symptom severity and comorbid conditions — has the potential to enhance treatment outcomes but remains an area requiring further research.

ABX-002's Novel TRβ Agonist Approach for Bipolar Depression

Recent research into bipolar depression has moved well beyond conventional monoaminergic pharmacology, with glutamatergic modulation emerging as one of the most clinically advanced avenues. NMDA receptor antagonists — particularly ketamine and its S-enantiomer esketamine — have demonstrated rapid and robust antidepressant effects in treatment-resistant bipolar depression across multiple randomized controlled trials, with significant symptom improvement occurring within hours of administration. Intranasal esketamine has shown comparable efficacy and safety to its intravenous counterpart, with no reported cases of mania or hypomania, distinguishing it from traditional antidepressants by its low mood-switch liability. Mechanistic investigations using dynamic causal modeling have further confirmed that AMPA- and NMDA-mediated glutamatergic signaling are central to ketamine's antidepressant response, with ketamine efficacy correlating with reduced NMDA and AMPA connectivity estimates in discrete extrinsic connections within the somatosensory cortical network. Beyond NMDA antagonism, other glutamatergic agents — including the glycine partial agonist GLYX-13 and its oral analogue NRX-1074, as well as mGluR5 modulators — have demonstrated varying degrees of preclinical and clinical promise.

Neuroinflammatory pathways represent a second major frontier in bipolar depression research. Elevated circulating pro-inflammatory cytokines — including IL-1, IL-6, and TNF-α — have been documented across depressive and manic states in bipolar disorder, with TNF-α and its receptors (TNF-R1 and TNF-R2) proposed as potential trait markers of the condition. TNF-α antagonists such as adalimumab, etanercept, and infliximab have been evaluated in clinical trials for their effects on depressive symptoms and mental health-associated quality of life, positioning TNF-α modulation as a candidate disease-modifying target. Clinical studies of lithium have further illuminated the inflammatory dimension of bipolar disorder: chronic lithium treatment decreases IL-2, IL-6, IL-10, and IFN-γ secretion from peripheral blood leukocytes, and lithium response correlates with TNF-α levels, with poor responders exhibiting higher TNF-α. A 6-month pharmaceutical intervention study also demonstrated that IL-1 and IL-6 levels decreased significantly in bipolar disorder patients during depressive episodes following treatment, with symptom improvement observed in parallel.

A third cluster of emerging targets spans several distinct neurobiological systems. Trace amine-associated receptor 1 (TAAR1) has attracted considerable interest: TAAR1 regulates the release of dopamine and serotonin, and selective TAAR1 agonists have shown efficacy in alleviating depressive and anxiety-like behaviors in animal models, with human TAAR1 gene loci clustering on chromosome 6q23 — a region whose mutations have been associated with susceptibility to bipolar disorder. TAAR5 antagonism has additionally been proposed as a potential anxiolytic mechanism. Among broader neurobiological targets, orexin receptor antagonists such as suvorexant and seltorexant have shown potential in mood disorders, while Sigma-1 receptor agonists including Blarcamesine and Pridopidine have demonstrated neuroprotective and cognitive-enhancing properties relevant to psychiatric indications. The P2×7 purinergic receptor, a key regulator of neuroinflammation, has been implicated in mood disorders, with pharmacological inhibition proposed to confer neuroprotective benefits. Collectively, these targets reflect a broadening mechanistic landscape for bipolar depression, though large-scale, placebo-controlled trials and biomarker-driven patient stratification remain necessary to translate preclinical findings into validated clinical applications.

Autobahn's ABX-002: Charting a New Course in Bipolar Depression

The U.S. FDA's clearance of Autobahn Therapeutics' Investigational New Drug (IND) application for ABX-002 marks a significant step forward in addressing the persistent challenges of bipolar depression. This move allows the company to initiate a Phase 2 trial for ABX-002 as an adjunctive treatment, targeting a patient population with a profound unmet medical need. Existing literature consistently highlights the limitations of current antidepressant therapies for many individuals with mood disorders, underscoring the urgent demand for novel therapeutic approaches.

The strategic decision to develop ABX-002 as an adjunctive therapy aligns with a growing understanding of complex mood disorders. Research indicates that glutamatergic system dysfunction is implicated in the pathophysiology of these conditions, and modulators of this system have shown promise, including rapid reductions in depressive symptoms. The success of other adjunctive glutamatergic approaches in maintaining improvement in severe bipolar depression after initial rapid-acting treatments provides a compelling precedent for ABX-002's potential.

However, the path forward is not without its complexities. As an adjunctive agent, ABX-002 will need to demonstrate a clear and clinically meaningful incremental benefit over existing standard-of-care treatments. The competitive landscape for novel glutamatergic modulators is also expanding, requiring ABX-002 to establish a differentiated profile. Furthermore, patients with bipolar depression often manage complex polypharmacy, making a robust safety and tolerability profile paramount to avoid drug-drug interactions and ensure patient adherence. Autobahn's concurrent evaluation of ABX-002 in major depressive disorder further broadens its potential impact, but the success in bipolar depression could significantly reshape treatment paradigms for this challenging condition.